<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Bristol-Myers Squibb Company</title>
	<atom:link href="http://www.stockbloghub.com/tag/bristol-myers-squibb-co/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMGN) Amgen&#8217;s Vectibix Offers Mixed Data From Trial</title>
		<link>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024</link>
		<comments>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024#comments</comments>
		<pubDate>Thu, 24 Sep 2009 20:20:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16024</guid>
		<description><![CDATA[Yesterday, Amgen (AMGN) presented data from a phase III trial of its Vectibix in combination with Folfiri (an irinotecan based chemotherapy) as a second-line treatment for metastatic colorectal cancer at the 2009 ECCO 15 &#8211; ESMO 34 European Multidisciplinary Congress in Berlin. In the trial, Vectibix significantly improved progression-free survival (PFS) in patients with tumors containing a specific gene known as KRAS. Tumor KRAS status was confirmed in 91% of the 1,186 patients enrolled in the trial, the highest number ever reported for a second-line trial. The combination treatment of Vectibix and Folfiri achieved the co-primary endpoint by improving the median PFS by 2 months (5.9 months versus 3.9 months) compared to Folfiri alone. The combination also showed significant improvement (35% versus 10%) in tumor response rate in patients. However, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech</title>
		<link>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986</link>
		<comments>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:57:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15986</guid>
		<description><![CDATA[After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at approximately $356 million. The tender offer will expire at 12:00 midnight, ET, on Oct. 19, 2009. As a reminder, Biogen had initially approached Facet with an offer of $15 per share on Aug. 17, 2009. However, Facet did not accept the offer as the company believed that it was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck&#8217;s Isentress Wins Approval from the Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560</link>
		<comments>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:03:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15560</guid>
		<description><![CDATA[The European Union (EU) recently expanded the approval of Merck’s (MRK) Isentress (raltegravir) for the first line treatment of HIV patients. Earlier, it was approved for patients who had not responded to other treatment options. In the US, following a recent Food and Drug Administration (FDA) approval, Isentress can be used in combination therapy for previously untreated patients as well. Isentress recorded worldwide sales of $172 million for the second quarter of 2009, an increase of 123% compared with the year-ago period. We believe the recent FDA and EU approval (for previously untreated patients) could increase the number of targeted patients considerably, leading to a significant rise in sales. We expect the drug to record more than $1 billion in revenues by 2011. Recently, at the 49th Interscience Conference on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol Myers Squibb Sells Indonesian Unit</title>
		<link>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384#comments</comments>
		<pubDate>Wed, 16 Sep 2009 22:34:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15384</guid>
		<description><![CDATA[Bristol Myers Squibb (BMY) yesterday announced that it would sell the Asian rights to its over-the-counter (OTC) drugs to Japan&#8217;s Taisho Pharmaceutical for $160 million. Taisho will also buy Bristol’s Indonesian unit, which manufactures and sells OTC and ethical pharmaceutical products, for $150 million. The deal is expected to close during the fourth quarter of this year. This is the latest in a series of deals signed by Bristol to focus on prescription drugs. Through this deal, the Japanese firm seeks to bolster its presence in markets where demand for self-medicating products is still growing. Furthermore, this transaction will help Japan&#8217;s biggest maker of non-prescription drugs to make its first full-fledged entry into Asia&#8217;s OTC drug market. The transaction  will enable Taisho to acquire certain product registrations, trademarks and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Producer Price Index for August Rises on Energy</title>
		<link>http://www.stockbloghub.com/2009/09/16/jnj-producer-price-index-for-august-rises-on-energy/15261</link>
		<comments>http://www.stockbloghub.com/2009/09/16/jnj-producer-price-index-for-august-rises-on-energy/15261#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:59:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Colgate-Palmolive Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15261</guid>
		<description><![CDATA[The producer price index for August came in at a much higher-than-expected 1.7% increase for the month, following a 0.9% decline in July and a 1.8% increase in June. The consensus expectation was for a rise of just 0.8%. However, it was almost all because of higher energy costs. Core (ex food and energy) inflation was just 0.2% (just a notch higher than the 0.1% expected), following a 0.1% decline in July and a 0.5% increase in June. Energy prices rose 8.0% following a 2.4% decline in July and a 6.6% increase in June. On a year-over-year basis, producer prices were 4.3% lower, but in July they were 6.8% lower. Core producer prices are up 2.8% on a year-over-year basis. The year-over-year numbers are going to start looking much hotter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/jnj-producer-price-index-for-august-rises-on-energy/15261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Maintains Facet Biotech Offer</title>
		<link>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795</link>
		<comments>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795#comments</comments>
		<pubDate>Thu, 10 Sep 2009 02:38:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14795</guid>
		<description><![CDATA[Yesterday, Biogen Idec (BIIB) reiterated its intention to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, even though Facet turned down the offer saying it was not in the best interests of its shareholders. The offer price represents a 64% premium to Facet’s closing price on September 3, 2009. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on August 17, 2009. However, Facet did not accept the offer as the company believed that the offer price was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. According to Biogen, the Trubion deal led to a reduction in Facet’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Drug Under FDA Review</title>
		<link>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:32:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14451</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Company (BMY) announced the acceptance of a biologic license application (BLA) for belatacept by the U.S. Food and Drug Administration (FDA). The candidate is in late-stage development for treating kidney transplant patients. The agency has set May 1, 2010, as the Prescription Drug User Fee Act (PDUFA) action date. The biological product is being developed internally and is a fusion protein with novel immunosuppressive activity targeted to prevent solid organ transplant rejection. The company owns a patent covering belatacept as a composition of matter which expires in the U.S. in 2021. We believe that the candidate can prove to be a suitable alternative for transplant patients in this market with huge unmet medical needs. The market encompasses therapies that must be taken lifelong, ensuring a steady stream ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor</title>
		<link>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333</link>
		<comments>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:46:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14333</guid>
		<description><![CDATA[Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion. The market was abuzz with rumors yesterday regarding the potential takeover. The rumors led to a 26.46% increase in Sepracor’s stock price. Trading was halted in the afternoon with Sepracor shares closing at $22.80. This acquisition is the latest in a series of deals conducted by Japanese companies that are looking to tap the U.S. pharmaceutical market – the biggest in the world. Last year, we saw four such deals take place including Eisai’s acquisition of MGI Pharma, Takeda’s acquisition of Millennium Pharma and Shionogi’s acquisition of Sciele. Finally, Daiichi-Sankyo acquired a stake ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Completes Acquisition</title>
		<link>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191</link>
		<comments>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191#comments</comments>
		<pubDate>Wed, 02 Sep 2009 19:38:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14191</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) yesterday announced the completion of the $2.4 billion acquisition of Medarex, Inc.  Following the completion of the deal, Medarex has become a wholly-owned subsidiary of Bristol-Myers. The deal was funded by Bristol-Myers from available cash. The merger became effective on Sept 1. Consequently, the acquired entity will not trade on the Nasdaq Stock Market from Sept 2. As a reminder, Bristol-Myers initiated a cash tender offer to buy all outstanding shares of common stock of Medarex for $16.00 per share on July 28. The period expired on Aug 26 and the subsequent offering period ended on Aug 31. Approximately 90.7% of Medarex’s outstanding shares were tendered in favor of Bristol’s cash tender offer. Bristol-Myers acquired the remaining outstanding shares of Medarex common stock through a “short ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) A Step Forward for Bayer&#8217;s Atrial Fibrillation Drug</title>
		<link>http://www.stockbloghub.com/2009/08/31/bmy-a-step-forward-for-bayers-atrial-fibrillation-drug/13971</link>
		<comments>http://www.stockbloghub.com/2009/08/31/bmy-a-step-forward-for-bayers-atrial-fibrillation-drug/13971#comments</comments>
		<pubDate>Mon, 31 Aug 2009 20:41:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13971</guid>
		<description><![CDATA[The therapeutic area of Atrial Fibrillation (AF) is buzzing with news. We are pleased with the development made by Bayer Schering Pharma, a division of Bayer Healthcare in this field. The company completed patient enrollment in the phase III study for Rivaroxaban (Xarelto). The study aims to assess the efficacy and safety of this drug against Bristol-Myers Squibb’s (BMY) warfarin, which is primarily used for the prevention of stroke in AF patients. The study is expected to include about 14,269 patients spanning over 45 countries with results due by next year. Atrial fibrillation is the most common heart rhythm abnormality in the US. An estimated 3 million people in the US have atrial fibrillation, which affects about one in 10 people aged over 70. Rivaroxaban, jointly developed with Johnson and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/bmy-a-step-forward-for-bayers-atrial-fibrillation-drug/13971/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Buyout of Medarex Update</title>
		<link>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807</link>
		<comments>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:03:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13807</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Co. (BMY) announced that its cash tender offer to purchase all outstanding shares of common stock of Medarex Inc. (MEDX) expired on Aug. 26.  The tender offer was not extended, unlike the previous instance when the offer originally scheduled to close on August 24 was extended by two days. The cash tender offer saw 87.7% of Medarex shares outstanding, or a total of 119 million shares, being tendered. With an objective of acquiring the remaining Medarex stock, Bristol announced a subsequent offering period from yesterday until August 31, 2009, unless extended. The Bristol management believes that the completion of the deal would be hastened if more than 90% Medarex shares are tendered. Even if the new tender offer fails to attain this goal, the deal is expected ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Wider Label Approval for Bristol Myers Squibb Drug</title>
		<link>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696</link>
		<comments>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696#comments</comments>
		<pubDate>Fri, 28 Aug 2009 00:18:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13696</guid>
		<description><![CDATA[Bristol Myers Squibb Co. (BMY) yesterday announced the approval of a broader label for its rheumatoid arthritis drug Orencia by the U.S. Food and Drug Administration (FDA). The agency approved an addition to the label that supports the use of Orencia (abatacept) in patients suffering from moderate to severe rheumatoid arthritis, duration of which is less than or equal to two years. The drug that recorded global sales of $129 million in 2008 is designed to reduce symptoms of rheumatoid arthritis. However, it should not be administered along with tumor necrosis factor (TNF) antagonists and is not recommended for use in tandem with other biologic rheumatoid arthritis therapies. As a reminder, the drug was initially approved by the FDA in late 2005 and made commercially available in the U.S. in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Notified Johnson &amp; Johnson Intends to Stop Development of Risperidone</title>
		<link>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717</link>
		<comments>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13717</guid>
		<description><![CDATA[On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to continue with the development of the four-week long-acting injectable formulation of risperidone. A phase I study with the four-week formulation had been initiated in January 2009. Risperidone, which is marketed as Risperdal Consta, is Alkermes’ lead product. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). Risperdal Consta uses Alkermes&#8217; proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. The product is approved in more than 85 countries worldwide and is available in 60 countries. Risperdal Consta is superior to the first-generation Risperdal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LGND) Ligand Pharmaceuticals to Buy Neurogen</title>
		<link>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310</link>
		<comments>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:36:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Neurogen Corporation]]></category>
		<category><![CDATA[NRGN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13310</guid>
		<description><![CDATA[Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth quarter of this year, has been approved by both company boards. Additionally, Neurogen shareholders, representing approximately 33% of outstanding shares, have already given their nod in favor of the deal. The terms of the deal require Ligand to issue about 4 million new shares to Neurogen shareholders, which is equivalent to a purchase price of 16 cents per common share of Neurogen. Neurogen stockholders would hold 3% of the combined company. The transaction will give Ligand shareholders access to Neurogen&#8217;s partnership with Merck &#38; Co., ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XLV) Healthcare Debate &#8211; Some Potential Stock Winners</title>
		<link>http://www.stockbloghub.com/2009/08/21/xlv-healthcare-debate-some-potential-stock-winners/13059</link>
		<comments>http://www.stockbloghub.com/2009/08/21/xlv-healthcare-debate-some-potential-stock-winners/13059#comments</comments>
		<pubDate>Fri, 21 Aug 2009 19:10:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[ETF]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Health Care Select Sector SPDR]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machine]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Nike Inc.]]></category>
		<category><![CDATA[NKE]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>
		<category><![CDATA[Weight Watcher's International]]></category>
		<category><![CDATA[WTW]]></category>
		<category><![CDATA[XLV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13059</guid>
		<description><![CDATA[The ongoing debate about health care has become more focused on ideological lines than on what realistically can and should be done. Though not surprising, it is unfortunate. It would be wonderful if the conversation shifted to what changes can realistically be made and what changes should be made to prevent a worsening crisis. Here are some ideas, along with potential investment plays. Big Pharma Is Not Going Away Regardless of what you think about the drug companies, they are not going anywhere. The pharmaceutical lobby has made certain that it has a seat at the table and it seems probable that any new laws will benefit them. Even though some concessions will be made, the Obama Administration has quietly signaled a willingness not to pursue the most beneficial cost-saving ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/xlv-healthcare-debate-some-potential-stock-winners/13059/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Working on Medarex</title>
		<link>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058</link>
		<comments>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058#comments</comments>
		<pubDate>Fri, 21 Aug 2009 19:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13058</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Co. (BMY) extended its cash tender offer to purchase all outstanding shares of Medarex Inc. (MEDX) by two days to Aug. 26. Bristol-Myers offered to buy Medarex for $16 per share, or $2.1 billion in July. However, less than 9% of Medarex&#8217;s outstanding shares have been tendered till now. Last week, antitrust regulators approved the deal. With the acquisition of Medarex, Bristol-Myers will get the UltiMAb Human Antibody Development System, which produces high affinity, human antibodies for use in a broad range of therapeutic areas Incorporatedluding immunology and oncology. It will also obtain Medarex’s next-generation Antibody-Drug Conjugate  technology, which is a novel and proprietary platform that could open new fields in cancer treatment. Medarex’s has seven antibodies in clinical trials under its sole funding and is developing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/bmy-bristol-myers-working-on-medarex-analyst-blog/13058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb&#8217;s Plavix Patent Getting Review</title>
		<link>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837</link>
		<comments>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:57:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Glbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12837</guid>
		<description><![CDATA[Bristol-Myers Squibb (BMY) announced that its lead drug, Plavix, will be reviewed by the U.S. Patent and Trademark Office (PTO). Plavix is indicated for the reduction of the risk of heart attacks or strokes in patients with atherosclerosis (the build-up of plaque and hardening of the arteries). The drug is co-promoted with pharmaceutical giant Sanofi-Aventis (SNY). Plavix sales in the second quarter were $1,539 million, up 11%. Sales in 2008 were up 18% to $5.6 billion, making it one of the world’s best-selling pharmaceutical products. The patent of the antiplatelet blood thinner is expected to expire in November 2011, although the companies might win a six-month extension for conducting pediatric studies. Canada-based Apotex has requested the U.S. Patent and Trademark Office to review the patent as the company is looking to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Co. announced Medarex Acquisition Cleared Review</title>
		<link>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518</link>
		<comments>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518#comments</comments>
		<pubDate>Fri, 14 Aug 2009 23:54:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12518</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) yesterday announced that the regulatory review period for its cash tender offer to acquire Medarex Inc. (MEDX) has expired. On July 28, 2009, Bristol-Myers had initiated an offer to buy all outstanding shares of common stock of Medarex for $16 per share. The clearance of the review, necessary under the anti-trust law, allows the $2.1 billion deal to proceed. With the Medarex acquisition, Bristol-Myers will acquire the UltiMAb Human Antibody Development System, which produces high affinity, fully human antibodies for use in a broad range of therapeutic areas Incorporatedluding immunology and oncology. Bristol-Myers will also acquire Medarex’s next-generation Antibody-Drug Conjugate (ADC) technology, which is a novel and proprietary platform that could open new fields in oncology drug development. Medarex’ pipeline includes seven antibodies in clinical trials ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Drug Companies: A Powerhouse of Profits</title>
		<link>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849</link>
		<comments>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849#comments</comments>
		<pubDate>Sat, 09 May 2009 23:36:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=6849</guid>
		<description><![CDATA[by The Investment U Research Team A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost of $8 billion. The other a study that finds more Americans than ever are taking some sort of prescription for mental illness – 73% more than in 1996. What’s interesting, apart from the fact that we seem to be overmedicating as a society, is that the numbers of patients and the costs of treatments spell hundreds of billions in profits for healthcare and drug makers. Taking a look at the eleven largest, we find that their market caps total almost $900 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FDO) Family Dollar Stores, Inc. &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/16/fdo-family-dollar-stores-inc-growth-and-income-zacks-rank-buy-2/4365</link>
		<comments>http://www.stockbloghub.com/2009/03/16/fdo-family-dollar-stores-inc-growth-and-income-zacks-rank-buy-2/4365#comments</comments>
		<pubDate>Mon, 16 Mar 2009 22:35:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[BKE]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Buckle Inc.]]></category>
		<category><![CDATA[Family Dollar Stores Inc.]]></category>
		<category><![CDATA[FDO]]></category>
		<category><![CDATA[STE]]></category>
		<category><![CDATA[Steris Corporation]]></category>
		<category><![CDATA[YUM]]></category>
		<category><![CDATA[Yum! Brands Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4365</guid>
		<description><![CDATA[Family Dollar Stores, Inc. (FDO) keeps outperforming the Dow ($DJI), S&#38;P 500 (SPX) and NASDAQ (COMP), trading about 16% higher than a couple weeks ago, when it was previously featured as a Growth and Income pick. Earnings estimates have also increased recently. Sales Growth and a Guidance Boost The company recently reported a year-over-year increase of 8.7% in fiscal second-quarter net sales. Quarterly comparable store sales jumped 6.4% year-over-year. Family Dollar said sales in the quarter were driven by double-digit sales growth of consumable merchandise, admitting that sales of apparel were soft. FDO also hiked its earnings outlook, calling for second-quarter earnings of 59 to 61 cents per share. Analysts are forecasting 60 cents, 10 cents above last month&#8217;s estimates. For the fiscal year ending August 2009, analysts are projecting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/16/fdo-family-dollar-stores-inc-growth-and-income-zacks-rank-buy-2/4365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Co. &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/12/bmy-bristol-myers-squibb-co-growth-and-income-zacks-rank-buy/4263</link>
		<comments>http://www.stockbloghub.com/2009/03/12/bmy-bristol-myers-squibb-co-growth-and-income-zacks-rank-buy/4263#comments</comments>
		<pubDate>Thu, 12 Mar 2009 22:49:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4263</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) recently declared a quarterly dividend of 31 cents per share, noting that it is payable on May 1 to stockholders of record at the close of business on April 3. BMY boasts an industry-leading yield of 6%. Company Description Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer. Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the Middle East and Asia. Outstanding Income The company recently declared a quarterly dividend of 31 cents per share, noting that it is payable on May 1 to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/12/bmy-bristol-myers-squibb-co-growth-and-income-zacks-rank-buy/4263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol Myers Squibb &#8211; IPO offering of its Mead Johnson Nutrition (MJN) business</title>
		<link>http://www.stockbloghub.com/2009/02/18/bmy-bristol-myers-squibb-ipo-offering-of-its-mead-johnson-nutrition-mjn-business/2759</link>
		<comments>http://www.stockbloghub.com/2009/02/18/bmy-bristol-myers-squibb-ipo-offering-of-its-mead-johnson-nutrition-mjn-business/2759#comments</comments>
		<pubDate>Wed, 18 Feb 2009 16:11:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2759</guid>
		<description><![CDATA[Bristol Myers Squibb Co. (BMY) boasts a solid record of exceeding analysts’ earnings expectations, missing the consensus estimate only twice in more than 4 years. For the 2009 year, analysts see year-over-year earnings per share growth of 11%. The Street is forecasting earnings growth of 16% for the following year. Company Description Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer. Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the Middle East and Asia. An IPO Bristol-Myers feels confident enough, even amid current economic woes, to execute a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/18/bmy-bristol-myers-squibb-ipo-offering-of-its-mead-johnson-nutrition-mjn-business/2759/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb &#8211; Earnings came in 12% above analysts’ expectations</title>
		<link>http://www.stockbloghub.com/2009/02/03/bmy-bristol-myers-squibb-earnings-came-in-12-above-analysts%e2%80%99-expectations/2514</link>
		<comments>http://www.stockbloghub.com/2009/02/03/bmy-bristol-myers-squibb-earnings-came-in-12-above-analysts%e2%80%99-expectations/2514#comments</comments>
		<pubDate>Tue, 03 Feb 2009 22:07:03 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2514</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) recently reported a strong fourth quarter with earnings that were above expectations thanks to demand for BMY&#8217;s Abilify schizophrenia drug and Plavix blood-clot preventer. BMY Saw Growth in the Fourth Quarter The company recently announced fourth-quarter net sales from continuing operations of $5.2 billion, an increase of 4%, or 8% excluding foreign exchange impact, on a year-over-year basis. Earnings per share also surpassed the year-ago level, coming in 12% above analysts’ expectations. BMY topped Wall Street estimates by an average of 8% over the past 4 consecutive quarters. “In the quarter, and in the past year, we’ve taken decisive action as a BioPharma leader to become leaner and more agile,” said James M. Cornelius, chairman and chief executive officer. “I’m particularly pleased by our global commercial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/03/bmy-bristol-myers-squibb-earnings-came-in-12-above-analysts%e2%80%99-expectations/2514/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb &#8211; forecast represents a 23% increase over last year’s earnings</title>
		<link>http://www.stockbloghub.com/2008/12/18/bmy-bristol-myers-squibb-forecast-represents-a-23-increase-over-last-year%e2%80%99s-earnings-2/1782</link>
		<comments>http://www.stockbloghub.com/2008/12/18/bmy-bristol-myers-squibb-forecast-represents-a-23-increase-over-last-year%e2%80%99s-earnings-2/1782#comments</comments>
		<pubDate>Thu, 18 Dec 2008 22:34:32 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1782</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) offers a rewarding dividend yield of 5.5%. Lately, the company has been trading ahead of the Dow Jones ($DJI), S&#38;P 500 (SPX) and NASDAQ (COMP). Company Description Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer. The Nutritional segment, through its subsidiary Mead Johnson, develops infant formulas like Enfamil, as well as other nutritional products. Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the Middle East and Asia. Recent Events The company recently announced that it will cut another 10% of its work force ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/18/bmy-bristol-myers-squibb-forecast-represents-a-23-increase-over-last-year%e2%80%99s-earnings-2/1782/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

